

Status: Currently Official on 16-Feb-2025  
Official Date: Official as of 01-Dec-2020  
Document Type: USP Monographs  
DocId: GUID-E68E3468-294D-40BF-A0E9-CD4A6367EBC9\_2\_en-US  
DOI: https://doi.org/10.31003/USPNF\_M71588\_02\_01  
DOI Ref: d6egc

© 2025 USPC  
Do not distribute

# Pseudoephedrine Hydrochloride Oral Solution

**DEFINITION**  
Pseudoephedrine Hydrochloride Oral Solution contains NLT 90.0% and NMT 110.0% of the labeled amount of pseudoephedrine hydrochloride ( $C_{10}H_{15}NO \cdot HCl$ ).

**IDENTIFICATION**  
**Change to read:**  
• **A.** ▲The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.▲ (USP 1-Dec-2020)  
**Change to read:**  
• **B.**  
**Sample solution:** 5 mg/mL of pseudoephedrine from ▲a volume of Oral Solution equivalent to 120 mg of pseudoephedrine hydrochloride▲ (USP 1-Dec-2020) in 0.1 N [hydrochloric acid](#)  
**Acceptance criteria:** The *Sample solution* is dextrorotatory.

**ASSAY**  
**Change to read:**  
• **PROCEDURE**  
▲**Solution A:** 0.1 M [potassium phosphate](#), 1.0% [triethylamine](#), and 0.4% [phosphoric acid](#) in a mixture of [methanol](#) and [water](#) (10:90) prepared as follows. Dissolve 17.4 g of [potassium phosphate dibasic](#) in 800 mL of a mixture of [methanol](#) and [water](#) (10:90) into a 1-L volumetric flask. Pipet 10.0 mL of [triethylamine](#) and 4.0 mL of [phosphoric acid](#) into the flask. Dilute with a mixture of [methanol](#) and [water](#) (10:90) to volume.  
**Solution B:** 0.1 M [potassium phosphate](#), 1.0% [triethylamine](#), and 0.4% [phosphoric acid](#) in a mixture of [methanol](#) and [water](#) (50:50) prepared as follows. Dissolve 17.4 g of [potassium phosphate dibasic](#) in 800 mL of a mixture of [methanol](#) and [water](#) (50:50) into a 1-L volumetric flask. Pipet 10.0 mL of [triethylamine](#) and 4.0 mL of [phosphoric acid](#) into the flask. Dilute with a mixture of [methanol](#) and [water](#) (50:50) to volume.  
**Mobile phase:** See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	75	25
7	25	75
10	0	100
15	0	100
15.1	75	25
17	75	25

**Standard solution:** 0.3 mg/mL each of [USP Pseudoephedrine Hydrochloride RS](#) and [USP Sodium Benzoate RS](#) in [water](#)

**Sample solution:** Nominally 0.3 mg/mL of pseudoephedrine hydrochloride in [water](#). Prepare by adding a suitable amount of Oral Solution to an appropriate flask and diluting with [water](#) to volume.

#### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 257 nm

**Column:** 3.0-mm × 10-cm; 1.8-μm packing [L1](#)

**Column temperature:** 50°

**Flow rate:** 0.25 mL/min

**Injection volume:** 7 μL

#### System suitability

**Sample:** *Standard solution*

[NOTE—The relative retention times for sodium benzoate and pseudoephedrine are 0.85 and 1.00, respectively.]

#### Suitability requirements

**Resolution:** NLT 2.0 between sodium benzoate and pseudoephedrine

**Relative standard deviation:** NMT 2.0% for both sodium benzoate and pseudoephedrine

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of pseudoephedrine hydrochloride ( $C_{10}H_{15}NO \cdot HCl$ ) in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of pseudoephedrine from the *Sample solution*

$r_S$  = peak response of pseudoephedrine from the *Standard solution*

$C_S$  = concentration of [USP Pseudoephedrine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of pseudoephedrine hydrochloride in the *Sample solution* (mg/mL)▲ (USP 1-Dec-2020)

**Acceptance criteria:** 90.0%–110.0%

#### PERFORMANCE TESTS

##### • [UNIFORMITY OF DOSAGE UNITS \(905\)](#)

**For Oral Solution packaged in single-unit containers**

**Acceptance criteria:** Meets the requirements

##### • [DELIVERABLE VOLUME \(698\)](#)

**For Oral Solution packaged in multiple-unit containers**

**Acceptance criteria:** Meets the requirements

#### IMPURITIES

*Add the following:*

##### ▲ • ORGANIC IMPURITIES

**Solution A, Solution B, Mobile phase, Sample solution, and Chromatographic system:** Proceed as directed in the Assay.

**Standard stock solution:** Prepare as directed for the *Standard solution* in the Assay.

**Standard solution:** 0.6 μg/mL each of [USP Pseudoephedrine Hydrochloride RS](#) and [USP Sodium Benzoate RS](#) in [water](#) from the *Standard stock solution*

**Sensitivity solution:** 0.3 μg/mL each of [USP Pseudoephedrine Hydrochloride RS](#) and [USP Sodium Benzoate RS](#) in [water](#) from the *Standard stock solution*

#### System suitability

**Samples:** *Standard solution* and *Sensitivity solution*

#### Suitability requirements

**Resolution:** NLT 2.0 between sodium benzoate and pseudoephedrine, *Standard solution*

**Relative standard deviation:** NMT 6.0% for sodium benzoate, *Standard solution*

**Signal-to-noise ratio:** NLT 10 for sodium benzoate, *Sensitivity solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of any unspecified degradation product in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

$r_U$  = peak response of any unspecified degradation product from the *Sample solution*

$r_S$  = peak response of sodium benzoate from the *Standard solution*

$C_S$  = concentration of [USP Sodium Benzoate RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of pseudoephedrine hydrochloride in the *Sample solution* (mg/mL)

$F$  = relative response factor for sodium benzoate, 0.12

**Acceptance criteria:** See [Table 2](#).

**Table 2**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Pseudoephedrine	1.0	—
Any unspecified degradation product	—	0.2
Total degradation products	—	3.0▲ (USP 1-Dec-2020)

## SPECIFIC TESTS

**Change to read:**

### • REACTION

▲**Sample:** Oral Solution▲ (USP 1-Dec-2020)

**Acceptance criteria:** It is acid to litmus.

## ADDITIONAL REQUIREMENTS

• **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers.

**Change to read:**

• [USP REFERENCE STANDARDS \(11\)](#).

[USP Pseudoephedrine Hydrochloride RS](#)

▲ [USP Sodium Benzoate RS](#)▲ (USP 1-Dec-2020)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
PSEUDOEPHEDRINE HYDROCHLORIDE ORAL SOLUTION	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM22020 Small Molecules 2

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. 45(1)

**Current DocID:** GUID-E68E3468-294D-40BF-A0E9-CD4A6367EBC9\_2\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M71588\\_02\\_01](https://doi.org/10.31003/USPNF_M71588_02_01)

**DOI ref:** [d6egc](#)